who discovered semaglutide Florey discovery could help reduce global shortage of diabetes and weight loss drug Reflections on the discovery GLP-1
Description
Results depend on dose escalation, lifestyle factors, and individual metabolic response
In clinical trials, around 10 to 15 percent of the people who take the drugs are considered non-responders because they did not lose at least 5 percent of their body weight.
As the use of GLP-1 receptor agonists continues to expand for the treatment of type 2 diabetes and obesity, questions have emerged about their potential gastrointestinal side effectsparticularly gastroesophageal reflux disease (GERD)
Learn about common semaglutide side effects, from nausea to digestive issues
